Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives

被引:166
作者
Ali, Eunus S. [1 ,15 ,16 ]
Sharker, Shazid Md [2 ]
Islam, Muhammad Torequl [3 ,4 ]
Khan, Ishaq N. [5 ]
Shaw, Subrata [6 ]
Rahman, Md Atiqur [7 ]
Uddin, Shaikh Jamal [8 ]
Shill, Manik Chandra [2 ]
Rehman, Shahnawaz [9 ]
Das, Niranjan [10 ,11 ]
Ahmad, Saheem [9 ]
Shilpi, Jamil A. [8 ]
Tripathi, Swati [12 ]
Mishra, Siddhartha Kumar [13 ]
Mubarak, Mohammad S. [14 ]
机构
[1] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA, Australia
[2] North South Univ, Dept Pharmaceut Sci, Dhaka 1229, Bangladesh
[3] Ton Duc Thang Univ, Dept Management Sci & Technol Dev, Ho Chi Minh City, Vietnam
[4] Ton Duc Thang Univ, Fac Pharm, Ho Chi Minh City, Vietnam
[5] Khyber Med Univ, Inst Basic Med Sci, Peshawar 25100, Pakistan
[6] Broad Inst MIT & Harvard, 415 Main St, Cambridge, MA 02142 USA
[7] Mayo Clin, Div Hematol & Oncol, Scottsdale, AZ USA
[8] Khulna Univ, Life Sci Sch, Pharm Discipline, Khulna, Bangladesh
[9] Integral Univ, Dept Biosci, Lucknow, Uttar Pradesh, India
[10] Netaji Subhas Mahavidyalaya, Dept Chem, Udaipur, Gomati Tripura, India
[11] ICV Coll, Dept Chem, Belonia 799155, South Tripura, India
[12] Amity Univ, Amity Inst Microbial Technol, Noida 201313, India
[13] Dr Harisingh Gour Cent Univ, Sch Biol Sci Zool, Canc Biol Lab, Sagar 470003, MP, India
[14] Univ Jordan, Dept Chem, Amman 11942, Jordan
[15] Northwestern Univ, Feinberg Sch Med, Dept Biochem & Mol Genet, 303 E Super St, Chicago, IL 60611 USA
[16] Northwestern Univ, Feinberg Sch Med, Simpson Querrey Ctr Epigenet, 303 E Super St, Chicago, IL 60611 USA
关键词
Nanotechnology; Cancer therapy; Nanocarriers; Tumor microenvironment; Cancer diagnosis; Cancer treatment; PEGYLATED LIPOSOMAL DOXORUBICIN; ANTICANCER LIPID NANOPARTICLES; GRAPHENE-BASED NANOMATERIALS; PHASE-III TRIAL; DRUG-DELIVERY; TUMOR MICROENVIRONMENT; POLYMERIC NANOPARTICLES; LUNG-CANCER; BIOMEDICAL APPLICATIONS; PERSONALIZED MEDICINE;
D O I
10.1016/j.semcancer.2020.01.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nanotechnology is reshaping health care strategies and is expected to exert a tremendous impact in the coming years offering better healthcare facilities. It has led to not only therapeutic drug delivery feasibility but also to diagnostics. Materials in the size of nano range (1-100 nm) used in the design, fabrication, regulation, and application of therapeutic drugs or devices are classified as medical nanotechnology and nanopharmacology. Delivery of more complex molecules to the specific site of action as well as gene therapy has pushed forward the nanoparticle-based drug delivery to its maximum. Areas that benefit from nano-based drug delivery systems are cancer, diabetes, infectious diseases, neurodegenerative diseases, blood disorders and orthopedic-related ailments. Moreover, development of nanotherapeutics with multi-functionalities has a considerable potential to fill the gaps that exist in the present therapeutic domain. In cancer treatment, nanomedicines have superiority over current therapeutic practices as they can effectively deliver the drug to the affected tissues, thus reducing drug toxicities. Along this line, polymeric conjugates of asparaginase and polymeric micelles of paclitaxel have recently been recommended for the treatment of various types of cancers. Nanotechnology-based therapeutics and diagnostics provide greater effectiveness with less or no toxicity concerns. Similarly, diagnostic imaging holds promising future applications with newer nano-level imaging elements. Advancements in nanotechnology have emerged to a newer direction which use nanorobotics for various applications in healthcare. Accordingly, this review comprehensively highlights the potentialities of various nanocarriers and nanomedicines for multifaceted applications in diagnostics and drug delivery, especially the potentialities of polymeric nanoparticle, nanoemulsion, solid-lipid nanoparticle, nanostructured lipid carrier, self-micellizing anticancer lipids, dendrimer, nanocapsule and nanosponge-based therapeutic approaches in the field of cancer. Furthermore, this article summarizes the most recent literature pertaining to the use of nano-technology in the field of medicine, particularly in treating cancer patients.
引用
收藏
页码:52 / 68
页数:17
相关论文
共 218 条
[1]   Modulation of the Tumor Microenvironment for Cancer Treatment: A Biomaterials Approach [J].
Adjei, Isaac M. ;
Blanka, Sharma .
JOURNAL OF FUNCTIONAL BIOMATERIALS, 2015, 6 (01) :81-103
[2]   Theranostic applications of nanoparticles in cancer [J].
Ahmed, Naveed ;
Fessi, Hatem ;
Elaissari, Abdelhamid .
DRUG DISCOVERY TODAY, 2012, 17 (17-18) :928-934
[3]   Factors affecting the clearance and biodistribution of polymeric nanoparticles [J].
Alexis, Frank ;
Pridgen, Eric ;
Molnar, Linda K. ;
Farokhzad, Omid C. .
MOLECULAR PHARMACEUTICS, 2008, 5 (04) :505-515
[4]   The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca2+ signalling in steatotic hepatocytes [J].
Ali, Eunues S. ;
Hua, Jin ;
Wilson, Claire H. ;
Tallis, George A. ;
Zhou, Fiona H. ;
Rychkov, Grigori Y. ;
Barritt, Greg J. .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2016, 1863 (09) :2135-2146
[5]   Deranged hepatocyte intracellular Ca2+ homeostasis and the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma [J].
Ali, Eunus S. ;
Rychkov, Grigori Y. ;
Barritt, Greg J. .
CELL CALCIUM, 2019, 82
[6]   Calcium Signaling As a Therapeutic Target for Liver Steatosis [J].
Ali, Eunus S. ;
Petrovsky, Nikolai .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2019, 30 (04) :270-281
[7]   Metabolic Disorders and Cancer: Hepatocyte Store-Operated Ca2+ Channels in Nonalcoholic Fatty Liver Disease [J].
Ali, Eunus S. ;
Rychkov, Grigori Y. ;
Barritt, Greg J. .
STORE-OPERATED CA2+ ENTRY (SOCE) PATHWAYS: EMERGING SIGNALING CONCEPTS IN HUMAN (PATHO)PHYSIOLOGY, 2ND EDITION, 2017, 993 :595-621
[8]   Nano Drugs: Novel Agents for Cancer Chemo-Therapy [J].
Ali, Imran .
CURRENT CANCER DRUG TARGETS, 2011, 11 (02) :130-130
[9]  
Allen TC, 2008, ARCH PATHOL LAB MED, V132, P1551, DOI 10.1043/1543-2165(2008)132[1551:BCOMP]2.0.CO
[10]  
2